2,040 Shares in Solventum Co. (NYSE:SOLV) Acquired by Mufg Securities Americas Inc.

Mufg Securities Americas Inc. purchased a new position in shares of Solventum Co. (NYSE:SOLV) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,040 shares of the company’s stock, valued at approximately $135,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. New York Life Investment Management LLC increased its position in shares of Solventum by 0.7% in the fourth quarter. New York Life Investment Management LLC now owns 18,506 shares of the company’s stock worth $1,223,000 after acquiring an additional 136 shares in the last quarter. Blue Trust Inc. increased its position in shares of Solventum by 2.1% in the fourth quarter. Blue Trust Inc. now owns 7,872 shares of the company’s stock worth $549,000 after acquiring an additional 161 shares in the last quarter. EP Wealth Advisors LLC increased its position in shares of Solventum by 3.6% in the fourth quarter. EP Wealth Advisors LLC now owns 5,272 shares of the company’s stock worth $348,000 after acquiring an additional 181 shares in the last quarter. Avantax Advisory Services Inc. increased its position in shares of Solventum by 2.2% in the fourth quarter. Avantax Advisory Services Inc. now owns 8,835 shares of the company’s stock worth $584,000 after acquiring an additional 192 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its position in shares of Solventum by 48.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 687 shares of the company’s stock worth $45,000 after acquiring an additional 223 shares in the last quarter.

Solventum Trading Up 1.6%

NYSE SOLV opened at $74.08 on Friday. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $85.92. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The company has a market capitalization of $12.82 billion and a price-to-earnings ratio of 34.30. The company’s fifty day moving average price is $69.79 and its two-hundred day moving average price is $71.27.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Thursday, May 8th. The company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.15. The company had revenue of $2.07 billion for the quarter, compared to the consensus estimate of $2.02 billion. During the same quarter last year, the company earned $2.08 earnings per share. The company’s revenue was up 2.7% compared to the same quarter last year. As a group, research analysts predict that Solventum Co. will post 6.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

SOLV has been the subject of several recent research reports. Mizuho increased their price objective on shares of Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, March 3rd. The Goldman Sachs Group increased their price objective on shares of Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research report on Monday, March 3rd. Wells Fargo & Company increased their price objective on shares of Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Friday, February 28th. Piper Sandler dropped their price objective on shares of Solventum from $80.00 to $78.00 and set a “neutral” rating for the company in a research report on Friday, May 9th. Finally, Morgan Stanley upped their target price on shares of Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $79.00.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.